Holen Sie sich die Stockscreener-App
29.46
2.47%
0.71
Handel nachbörslich:
29.46
Schlusskurs vom Vortag:
$28.75
Offen:
$28.26
24-Stunden-Volumen:
211.97K
Relative Volume:
0.82
Marktkapitalisierung:
$1.34B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-161.15M
KGV:
-7.9302
EPS:
-3.7149
Netto-Cashflow:
$-138.61M
1W Leistung:
+8.79%
1M Leistung:
-1.01%
6M Leistung:
+126.79%
1J Leistung:
+0.00%
1-Tages-Spanne:
$28.25
$29.73
1-Wochen-Bereich:
$25.52
$29.97
52-Wochen-Spanne:
$12.24
$33.28
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
650-839-4360
Adresse
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
29.46 | 1.30B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Needham | Buy |
| 2026-04-07 | Eingeleitet | TD Cowen | Buy |
| 2026-03-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Alle ansehen
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com
Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus
Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Craig-Hallum initiates coverage of MapLight Therapeutics (MPLT) with buy recommendation - MSN
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria
MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com
MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan
MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks
T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan
A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView
MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus
MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks
MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo
[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan
What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan
MPLT SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MapLight Therapeutics CEO Christopher Kroeger sells $1.95 million in stock By Investing.com - Investing.com Australia
MapLight Therapeutics CSO Lillie Woodruff sells $20,389 of company stock - Investing.com UK
MapLight Therapeutics CSO Lillie Woodruff sells $20,389 of company stock By Investing.com - Investing.com Australia
MapLight Therapeutics CMO Foff sells $126,639 in stock - Investing.com UK
MapLight Therapeutics general counsel Kristopher Hanson sells $419,263 By Investing.com - Investing.com Canada
MapLight Therapeutics CMO Foff sells $126,639 in stock By Investing.com - Investing.com South Africa
MapLight Therapeutics CEO Christopher Kroeger sells $1.95 million in stock - Investing.com UK
MapLight Therapeutics general counsel Kristopher Hanson sells $419,263 - Investing.com India
MapLight Therapeutics (MPLT) CSO sells 721 shares in planned trade - Stock Titan
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2026 - MarketBeat
MapLight Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
MapLight plans two New York investor events with live webcasts - Stock Titan
Maplight Therapeutics Insider Sold Shares Worth $1,427,594, According to a Recent SEC Filing - Moomoo
Maplight Therapeutics Insider Sold Shares Worth $1,024,719, According to a Recent SEC Filing - Moomoo
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maplight Therapeutics Inc-Aktie (MPLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hanson Kristopher | General Counsel |
May 11 '26 |
Sale |
30.13 |
13,917 |
419,263 |
162,331 |
| Kroeger Christopher A. | Chief Executive Officer |
May 08 '26 |
Sale |
27.69 |
34,411 |
952,835 |
1,526,309 |
| Kroeger Christopher A. | Chief Executive Officer |
May 07 '26 |
Sale |
28.65 |
20,100 |
575,797 |
1,560,720 |
| Kroeger Christopher A. | Chief Executive Officer |
May 11 '26 |
Sale |
30.11 |
13,980 |
421,002 |
1,512,329 |
| Foff Erin Pennock | Chief Medical Officer |
May 07 '26 |
Sale |
28.54 |
4,438 |
126,640 |
346,059 |
| Lillie James Woodruff | Chief Scientific Officer |
May 07 '26 |
Sale |
28.28 |
721 |
20,390 |
242,729 |
| Setia Vishwas | Chief Financial Officer |
May 04 '26 |
Sale |
28.11 |
14,904 |
418,930 |
377,723 |
| Setia Vishwas | Chief Financial Officer |
May 05 '26 |
Sale |
28.20 |
10,903 |
307,444 |
366,820 |
| Setia Vishwas | Chief Financial Officer |
May 06 '26 |
Sale |
28.24 |
10,564 |
298,345 |
356,256 |
| Foff Erin Pennock | Chief Medical Officer |
May 06 '26 |
Sale |
28.76 |
24,052 |
691,749 |
350,497 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):